These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 18634698)

  • 21. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis and formulary decision making in England: findings from research.
    Williams IP; Bryan S
    Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared.
    Cairns J
    Health Policy; 2006 Apr; 76(2):134-43. PubMed ID: 15982779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Technology assessment and coverage decision making.
    McGivney WT
    AAPPO J; 1994; 4(5):11-2, 14-7. PubMed ID: 10150666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
    Littlejohns P; Barnett D; Longson C;
    Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Working with NICE.
    Adams C
    J Fam Health Care; 2007; 17(4):113-4. PubMed ID: 17824208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
    Davies E; Littlejohns P
    J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans.
    Barton P
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv32-iv38. PubMed ID: 21859704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canada's National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization.
    Ismail SJ; Langley JM; Harris TM; Warshawsky BF; Desai S; FarhangMehr M
    Vaccine; 2010 Apr; 28 Suppl 1():A58-63. PubMed ID: 20412999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.
    Miners AH; Garau M; Fidan D; Fischer AJ
    BMJ; 2005 Jan; 330(7482):65. PubMed ID: 15601681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health technology assessment for the NHS in England and Wales.
    Woods K
    Int J Technol Assess Health Care; 2002; 18(2):161-5. PubMed ID: 12053415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Getting to 'smart' health care.
    Clancy CM
    Health Aff (Millwood); 2006; 25(6):w589-92. PubMed ID: 17090557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [More care for a limited budget; a case for a better use of the efficiency criteria].
    Rutten FF; Brouwer WB
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2254-8. PubMed ID: 12481524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involving stakeholders in healthcare decisions--the experience of the National Institute for Health and Clinical Excellence (NICE) in England and Wales.
    Culyer AJ
    Healthc Q; 2005; 8(3):56-60. PubMed ID: 16078403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down the road to product analysis, step by step. Medical Alley's Cost-Effectiveness Task Force.
    Mater Manag Health Care; 1995 Sep; 4(9):24. PubMed ID: 10151136
    [No Abstract]   [Full Text] [Related]  

  • 39. Introducing the National Institute for Health and Clinical Excellence.
    Jaques H
    Eur Heart J; 2012 Sep; 33(17):2111-2. PubMed ID: 23106069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.